🇺🇸 FDA
Pipeline program

ADCLEC.syn1 CAR T cells

23-002

Phase 1 mab active

Quick answer

ADCLEC.syn1 CAR T cells for Acute Myeloid Leukemia is a Phase 1 program (mab) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).

Program details

Company
Takeda Pharmaceuticals International AG
Indication
Acute Myeloid Leukemia
Phase
Phase 1
Modality
mab
Status
active

Clinical trials